Clinical trials: Peripheral Nervous System Diseases
Diabetic Neuropathy
A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain
A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.
- Trial name
- NCT01820715
- Testing
- 600㎍ of DA-3030 Injection
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Diabetic Peripheral Neuropathic Pain
Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management
This is a multicenter, randomized, open-label, parallel, Phase 4 clinical trial to compare efficacy and safety of gabapentin/B-complex versus pregabalin in diabetic peripheral neuropathy pain (DPNP) management.
- Trial name
- NCT01364298
- Testing
- Gabapentin/B-complex, Pregabalin
- Where
- Mexico
- Volunteers
- 353 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Postherpetic Neuralgia
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
This study aims to determine whether MK-8291 is effective in reducing pain in participants with post-herpetic neuralgia (PHN) with allodynia.
- Trial name
- NCT02336555
- Testing
- MK-8291
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
- Trial name
- ReNeu (NCT03962543)
- Testing
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Where
- 43 sites in United States
- Volunteers
- 114 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire
Chronic Peripheral Neuropathy Pain in Diabetics
A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
This study is to evaluate the long-term efficacy and safety of two dosages of bicifadine SR (600 mg/day and 1200 mg/day) for up to 52 weeks in reducing chronic peripheral neuropathy pain due to diabetes in adult outpatients.
- Trial name
- NCT00597649
- Testing
- Bicifadine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- XTL Biopharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199).
- Trial name
- NCT07188844
- Testing
- Batoclimab
- Where
- 30 sites in United States, Argentina and 9 more
- Volunteers
- 26 people
- Sponsor
- Immunovant Sciences GmbH
Diabetic Neuropathies, Neuropathic Pain
Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy
This study evaluates the analgesic effect of Omnitram for the treatment of painful diabetic neuropathy. Each subject with diabetic neuropathy will be treated for four weeks with Omnitram and for four weeks with placebo.
- Conditions
- Diabetic Neuropathies, Neuropathic Pain, Pain, Chronic
- Trial name
- NCT03664921
- Testing
- Omnitram Oral Tablet
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Syntrix Biosystems, Inc.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Gaucher Disease, Gaucher Disease, Type 1
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD.
- Trial name
- NCT05487599
- Testing
- LY3884961
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 8 people
- Sponsor
- Prevail Therapeutics
Neuropathic Pain, Phantom Limb Pain
Clinical Evaluation of the Medical Device (MD) (Caloprothese Connected Kit, CCK)
Neuropathic pain is common in limb amputees and causes reductions in activity and participation as well as impaired quality of life.
- Trial name
- KCC (NCT04748484)
- Testing
- KCC Active or inactive
- Where
- 4 sites in France
- Volunteers
- 12 people
- Sponsor
- Gregand Innovations
Familial Amyloid Polyneuropathy
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP). Deposition of TTR amyloid is associated with a variety of human diseases.
- Trial name
- NCT00409175
- Testing
- Fx-1006A
- Where
- 10 sites in United States, Argentina and 7 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Amyloid Cardiomyopathy
Open-Label Study of AG10 in Patients With Cardiomyopathy
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
- Trial name
- NCT03536767
- Testing
- Acoramidis
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Cervical Disc Degeneration
Real World Data Collection on the Synergy Cervical Disc
This trial is a real world data (RWD) collection observational study, comprised of both prospective and retrospective arms, that will examine the safety and effectiveness of the Synergy Cervical Disc System in patients with…
- Trial name
- NCT05305430
- Testing
- Synergy Cervical Disc System
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Synergy Spine Solutions
Diabetic Peripheral Neuropathy
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic…
- Trial name
- NCT00553592
- Testing
- Bicifadine
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- XTL Biopharmaceuticals
Peripheral Neuropathy, Neuropathic Pain
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of…
- Trial name
- NCT00603265
- Testing
- ADL5859, Duloxetine
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Painful Diabetic Neuropathy
A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT06383702
- Testing
- pregabalin sustained-release tablets
- Volunteers
- 358 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Diabetic Neuropathies
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to diabetic peripheral neuropathy.
- Trial name
- NCT00380913
- Testing
- Cesamet™ (nabilone)
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- NEMA Research, Inc.
Chronic Low-Back Pain, Refractory Pain
Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)
The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic…
- Conditions
- Chronic Low-Back Pain, Refractory Pain, Neuropathic Pain
- Trial name
- NCT04479787
- Testing
- Spinal Cord Stimulation, Conventional Medical Management
- Where
- 30 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Devices